

SYNTHESIS OF TPA TRIS(PYRIDIN-2-YLMETHYL) AMINE LIGANDS CONTAINING ELECTRON DONOR GROUPS IN α -SUBSTITUTED ON THE REACTION OF THE METAL CENTER OF IRON(II) COMPLEXES WITH MOLECULAR OXYGEN IN THE PRESENCE AND ABSENCE OF THE SUBSTRATE

Dr. NASSER THALLAJ

Assistant Professor, Pharmaceutical Chemistry and Drug Quality Control Department, Faculty of Pharmacy, Al-Rachid Private University, Damascus, Syria.
E-mail: profthallaj@gmail.com

ABSTRACT

This report describes how the coordination of FeCl_2 with tris(pyridin-2-ylmethyl)amine (TPA) ligands offers the possibility to activate molecular dioxygen in biomimetic processes. . It includes all processes that are used for larger oxidation reactions that are carried out in nature under certain conditions. The aim of this article is to present the result of a thorough study for complex coordinations involving ligands substituted by groups known as electron donors. It demonstrates how ligands with methoxy substituents are likely to be demethylated, and therefore provides moieties that are potentially synthetically useful. Aiming to modulate the electronic properties at the metal center, a new type of ligand $(\text{MeO})_2\text{TPA}$ was prepared and the complex of $(\text{MeO})_2\text{TPAFeCl}_2$ was probed by UV-visible light; ^1H RMN paramagnetic and conductivity. The effect of the m -substituted (MeO) group on the structure as well as the effect of the substitution on the oxygenation of the complex was verified. Subsequently, the reactivity of the complex towards molecular oxygen in the absence of substrate is checked by UV-visible, ^1H -RMN paramagnetic and radiocrystallography. In addition, reactivity in the presence of substrate is tested.

Keywords: Electron donor Biomimetic, tris(pyridin-2-ylmethyl)amine, $(\text{MeO})_2\text{TPA}$, (MeO) in α -substituted,iron(II), Molecular dioxygen activation.

Introduction

Hydroxylation reactions that take place in the presence of molecular oxygen, iron(II), and tetrahydrobiopterin (BH_4) [1] are found in several biological processes. Tryptophan hydroxylase (TrpH), catalyzes the conversion of L-tryptophan to 5-hydroxytryptophan (serotonin, 5-HT), as shown in Figure 1. Serotonin is known to play an important role in many biological functions [1-8]. Due to the sequential and structural homology and the similarity of the chemical transformations that take place by phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TyrH) and tryptophan hydroxylase (TrpH), it is generally assumed that these three enzymes have a similar hydroxylation mechanism [1,9-13].




Figure 1: Conversion of L-Tryptophan to 5-hydroxytryptophan by Tryptophan hydroxylase (TrpH).BH₄: tetrahydrobiopterin; 4a-OH-BH₂: hydroxydihydrobiopterin; AAD:Aromatic amino acid decarboxylase.

Previously, mechanistic studies have shown that the FeII center and the organic cofactor are required for aromatic hydroxylation [9,14]. To date, the study of catalytic mechanisms has relied mainly on kinetic analysis, including the study of isotope effects. It was concluded that dioxygen has the ability to bridge the active site and the hydroxylated carbon of pterin. Studies have been performed on TyrH in the presence of oxygen ¹⁸O₂ [15] and have suggested the absence of Fe-Oxy as an intermediate. It is postulated that molecular oxygen coordinates weakly, rather at a hydrophobic site on the protein between iron and pterin. These results combined with previous studies indicate that electron transfer from BH₄ to oxygen forms a superoxide anion as the first reactive intermediate. This radical pair would then couple to form an intermediate type 4a peroxytetrahydropterin. The position of pterin relative to the active iron site as observed in the structures of the three hydroxylases [12,16,17] suggests that the intermediate of 4a-peroxytetrahydropterin can then coordinate by bridging with iron, which is also suggested has been reported by several groups [18-22] (Figure 2). The iron peroxypterin formed is later converted by heterolytic cleavage into 4a-HO-BH₂ and FeVI-oxo, which would then be responsible for the hydroxylation of the amino acid.




Figure 2: Hydroxylation reaction mechanism for the three hydroxylases, according to reference 16.

Materials and methods

Synthesis of 2-methoxy-6-Methylpyridine [26]. :

6.10 g (153mmoles) of 60% NaH are washed with hexane and the mineral oil is extracted several times under argon until obtaining NaH without oil (pure NaH). 12 g (70mmoles) of 2-Bromo-6-Methylpyridine are dissolved in 80 ml of DMF, the solution is added to the NaH gradually over 15 minutes. The temperature of the medium is adjusted to 0 ° C using an ice bath under argon. The medium becomes very thick and the temperature does not exceed 0 ° C. 6.1 cm³ (153mmol) of methanol are added gradually over 5 minutes. The reaction mixture is refluxed for 3 hours at 80 ° C. The solution obtained is allowed to cool to room temperature. The product is extracted several times with ether. At the end, the transparent pale yellow solution obtained is washed several times with distilled water. Then, the organic phase is dried over MgSO₄ then filtered and evaporated. This transparent pale yellow liquid is distilled under reduced pressure (P = 15 mmHg). The fraction of the desired product was collected between 80 and 85 ° C, it is a colorless liquid.

RMN¹H, (CDCl₃, □□, ppm) :7.35-7.31, (1H_γ, m) 6.62-6.60 (1H_β, d, J=6); 6.48-6.45 (1H_{β'},d, J=9); 3.86,(s, 3H,OCH₃); 2.28, (s, 3H,CH₃).

Synthesis of 2-methoxy-6-Bromomethylpyridine [26]:

Into a solution of 2-methoxy-6-methyl pyridine (12g, 97.5 mmoles) in 200ml of carbon tetrachloride CCl₄ are introduced 20.82 g of N-bromosuccinimide (117.3 mmoles) and 675 mg of azobisisobutyronitrile (2.79 mmoles). The reaction mixture is brought to reflux (90 ° C.) for 5 hours. At the end, the solution is evaporated to dryness. The product taken up in 200 ml of toluene. The precipitate which forms is filtered off and the yellow solution is concentrated. The product is purified by chromatography column on silica mounted in toluene. The separation is followed by thin layer chromatography (TLC). This is the third fraction that contains the desired product. The product 2-methoxy-6-Bromomethylpyridine is a transparent liquid obtained with a yield of 50% (mass obtained: 9.85 g)

RMN¹H : (CDCl₃, δ, ppm) 7.54-7.47, (t,1H) 6.96-6.96 (d,1H); 6.64-6.61 (d,1H); 4.43, (s,2H); 3.91(s,3H).

Synthesis of 1-(5-methoxypyridin-2-yl)-N-((6-methoxypyridin-2-yl)methyl)-N-(pyridin-2-ylmethyl)methanamine ((MeO) 2TPA):

2 g (9.9 mmol) of 2- (bromomethyl) -6-methoxypyridine and 0.925 g (4.95 mmol) of 2-picolylamine are introduced into a flask. About 2 g of Na₂CO₃ and about 200 ml of ethanol are added. The medium is heated under reflux for 14 hours at 95 ° C. The treatment procedure is identical to that for (MeO) TPA. The product is purified by chromatography on an alumina column mounted with DCM containing 10% methanol.

(MeO) 2TPA has an orange-brown color and has a very hygroscopic character (Yield: 80%, mass obtained: 1.697 g).

Elemental analysis:

Calculated for (C₂₀H₂₂N₄O₂). C : 68,65 ; H : 6,33 ; N : 1,99.

Calculated for (C₂₀H₂₂N₄O₂)₃+H₂O : C : 67,40 ; H : 6,41 ; N : 15,72.

Obtained for ((MeO)₂TPA)₃.H₂O . C : 67,89 ; H : 6,342 ; N : 15,51.

RMN ¹H (300 MHz, CDCl₃) : δ (ppm) 3,83 (s, 4H,2CH₂); 3,85 (s, 6H,2CH₃) ; 3,98 (s, 2H,CH₂);6,54-6.51 (d, 1H) ; 7.07-7,08 (d, 1H) ; -7.43-7,48 (t, 2H) ; 7,56-7.60 (t, 1H) ; 7,66-7.68 (d, 1H) ; 8.44-8,46 (d, 1H, α-pyridine).

RMN ¹³C : 163(2C-OMe) ; 159(C); 156(2xC) ; 148(CH) ; 138(2xCH) ; 136(CH) ; 122(CH) ; 121(CH) ; 115(2xCH) ; 108(2xCH) ; 60(CH₂); 59(2 CH₂) ; 53(2CH₃) .

Procedure for determining the molar conductivity of a complex.

The measurements are taken at 295K.4 ml of degassed dry acetonitrile are introduced into the measuring cell, and the relative conductivity of the blank is measured (A). The relative conductivity of the sample dissolved in 4 ml of the same solvent is then measured (B). The conductivity of the compound is obtained by subtracting B – A. The molar conductivity is obtained by the ratio (B – A) / Complex concentration.

In the case of Bis-(MeO)TPAF₂Cl₂, the ligand is first introduced into the cell. The metallation is carried out in situ, by adding a stoichiometric quantity of FeCl₂ which is excessively measured.

Common procedure for the metallation of all ligands with ferrous chloride.

The principle of this reaction is to oppose one equivalent of ferrous chloride to one equivalent of ligand. In practice, a slight excess of ligand (5 to 10%) is used: this allows complete complexation of the metal, and the excess ligand is easy to remove by washing with ether or THF. This reaction takes place in the absence of Schlenk tube air. The solvents used are all distilled and degassed before use. The filtrations are carried out under overpressure by means of filter cannulas.

The standard procedure as published is shown below:

0.9 Equivalents of ferrous chloride in solution in THF are added by cannula to a solution of 1.0 equivalent of Ln ligand in THF. The color quickly turns to orange-yellow, and the reaction medium is kept under stirring for at least 2 hours at room temperature.

The solvent is then evaporated in vacuo and the complex extracted with acetonitrile. After filtration and concentration, a yellow-orange solid is obtained by slow addition of diethyl ether. The solid thus obtained can be recrystallized by adding ether to a solution in acetonitrile. After drying with a vacuum pump, the solid is characterized by different techniques. The yields of own products are between 85 and 90%.

General method for the oxidation of cyclohexane:

5 cm³ of acetonitrile and 270 μ L of cyclohexane are introduced into a Schlenk tube, which are degassed and then 0.005 mmol of the complex is dissolved therein. One to two drops of zinc amalgam are then added, the whole is kept under stirring. The oxygen in a flask is then gradually added to the solution. One to two hours is enough for the mixture to become cloudy, this indicates that the catalyst precipitates at the bottom of the Schlenk tube, the reaction is complete. 4.9 μ L of acetophenone are added to the solution and the whole is filtered through Celite. Gas chromatographic analysis follows.

Results and discussion

The preparation of the starting materials substituted in the 2-position is relatively simple. For 2-bromo-6-methylpyridine, a pressure of 15 mmHg and a temperature of 70-85°C gives an oil of white or pale yellow color. At room temperature, this oil becomes more viscous and solidifies in the refrigerator. For the product 2-methoxy-6-methylpyridine [34], the distillation was performed under 10 mmHg and at 50°C resulting in the recovery of a pale yellow liquid. These products are characterized by their ¹H NMR spectrum.





Figure 3: i): Br₂, HBr, NaNO₂, H₂O, 0°C, ii) : NaH , methanol, DMF, 3h, 100°C , iii): NBS, AIBN, CCl₄, reflux 15h, iv): Na₂CO₃ in CH₃CN reflux for 16h.

In fact, we know that this trident ligand is not isolable under these conditions because, once formed, it reacts much faster than the starting amine on the 2-methoxy-6-bromomethylpyridine derivative to form the tripod-di-methoxy to form [37]. Tripods of

the formula R2TPA are generally white solids that can be purified by chromatography (the synthesis of MeO2TPA has already been described and is known in our laboratory [30-39]). They are obtained in the microcrystalline state with yields of around 80% depending on the preparation (Figure 3). They are characterized by ¹H-NMR ¹³C, spectroscopy, elemental analysis.

Complexation of ligand (MeO)₂TPA

The ligands obtained and described above, were metallized with anhydrous ferrous chloride. Anhydrous FeCl₂ is a white solid.



The reaction is very simple and involves the use of one equivalent of ligand relative to the metal salt under strictly anhydrous conditions and under an argon atmosphere. The solvents are therefore freshly distilled using appropriate desiccants and subjected to extensive cryogenic degassing before use. The methodology used is that known as the Schlenck technique. In principle and for practical reasons of further processing, a 10% excess of ligand with iron(II) chloride. The yields of isolated products are generally between 80 and 90%. It is very likely that the reaction is quantitative, but more or less important amounts are lost during the treatment, which here is carried out entirely under an inert atmosphere. In the solid state, the compounds z. B. with an inverted argon funnel for a few seconds quickly handled from the Schlenck tube.

The solids obtained are generally sufficiently soluble in nitriles to be studied in solution in this type of solvent. The methodology used for their characterization is simple and consists of using the following techniques:

- UV-visible absorption spectroscopy.
- Paramagnetic Nuclear Magnetic Resonance.
- Electrochemical measurements: conductimetry.
- X-ray diffraction on single crystals when possible.

UV-visible and conductimetry




Figure 4 : The UV-visible spectrum for the (MeO)₂TPAFcCl₂ complex.


We can see, on spectrum shown on Figure 4, the presence of a rather weak absorption at around 340 nm. Indeed, this wavelength is too short to come from MLCT transition, but it corresponds perfectly to the emergence as described in Table 1.

In general, at the onset of oxygenation of octahedral compounds, MLCT absorption still clearly defined. This is not really visible here. We can easily assume that we are in the presence of a complex whose geometry is of the bipyramid type with a trigonal base.

UV-visible, λ , nm (ϵ , $\text{mmol}^{-1}\cdot\text{cm}^2$)	Conductimetry	
$\square \Rightarrow \square^*$	MLCT	Λ , $\text{S}\cdot\text{mol}^{-1}\cdot\text{cm}^2$
279.0 (8887)	340 (1247.7)	29.08


Table 1: the value of absorption in UV- visible spectrum and the conductimetry of complex MeO₂TPAFcCl₂ .

RMN ^1H :



It can be seen on this spectrum that the lines are wide (Figure 5). Qualitatively, this spectrum differs from the previous ones and is quite close to those observed for complexes of bipyramid geometry with a trigonal base, of the $\text{Br}_2\text{TPAFeCl}_2$ type [23].

We were unable to obtain single crystals for this compound. The presumed structure of the resulting compound is the following:



Oxygenation of $(\text{MeO})_2\text{TPAFeCl}_2$.

The oxygenation reaction of $(\text{MeO})_2\text{TPAFeCl}_2$ is faster than the previous one (Figure 6). The spectrum stops changing after about 9 hours, and a net absorption is observed at $\lambda = 340$ nm.




Figure 6 : the oxygenation reaction of the complex $(\text{MeO})_2\text{TPAFcCl}_2$ followed by UV-visible spectroscopy.

The progressive absence of any detecting signals was the main effect of the oxygenation process in 1H NMR tube. On the other hand, there was a significant amount of free ligand appearing in the tubes, and it was difficult to detect anything else: in fact the oxygenated form precipitated in the NMR tube (Figure 7).




Figure 7 : The ¹H NMR spectrum of the oxygenation reaction product of the $(\text{MeO})_2\text{TPAFcCl}_2$ complex.

Structure of the final compound

By covering a solution of oxygenated complex with diethyl ether, a single crystals could be obtained with the following mesh parameters:

Triclinic system, space group P-1. $a = 10.3810(2) \text{ \AA}$, $b = 12.3130(3) \text{ \AA}$, $c = 15.3210(4) \text{ \AA}$; $\alpha = 97.1020(4)^\circ$, $\beta = 109.5050(9)^\circ$, $\gamma = 109.7150(12)(5)^\circ$, $V = 1675.02(7)$, $Z = 2$.




Figure 8: Mercury diagram of the $(\text{MeO})_2\text{TPAFeClOFeCl}_3$ complex obtained by oxygenation of the $(\text{MeO})_2\text{TPAFeCl}_2$ complex.

A Mercury diagram is shown in Figure 8. The compound which crystallizes is a neutral, asymmetric binuclear species comparable to that described previously [43], with the bifluorinated ligand. The main metal-ligand distances and angles are given in Table 2.

(MeO)₂TPAFeClOFeCl₃	
Distances	Angles
Fe1 O7 1.755(3)Å	O7 Fe1 Cl5 110.46(10)° O7 Fe1 Cl6 111.52(11)° Cl5 Fe1 Cl6 108.63(6)° O7 Fe1 Cl4 112.38(11)° Cl5 Fe1 Cl4 107.20(5)° Cl6 Fe1 Cl4 106.45(6)°
Fe1 Cl5 2.2293(12)Å	O7 Fe2 N4 95.15(13)° O7 Fe2 N2 104.27(14)° N4 Fe2 N2 85.24(12)° O7 Fe2 N3 106.06(14)° N4 Fe2 N3 81.34(13)° N2 Fe2 N3 147.73(12)°
Fe1 Cl6 2.2291(14)Å	O7 Fe2 N1 173.09(13)° N4 Fe2 N1 78.11(12)° N2 Fe2 N1 73.88(12)° N3 Fe2 N1 74.69(12)° O7 Fe2 Cl3 97.84(10)° N4 Fe2 Cl3 166.85(9)° N2 Fe2 Cl3 93.48(9)° N3 Fe2 Cl3 93.09(9)° N1 Fe2 Cl3 88.95(9)°
Fe1 Cl4 2.2395(13)Å	Fe1 O7 Fe2 167.0(2)° C11 N1 Fe2 106.6(2)° C19 N1 Fe2 106.2(2)° C12 N1 Fe2 110.9(2)° C15 N2 Fe2 125.8(3)° C18 N2 Fe2 115.8(3)°
Fe2 O7 1.766(3)Å	
Fe2 N4 2.148(3)Å	
Fe2 N2 2.204(3)Å	
Fe2 N3 2.211(3)Å	
Fe2 N1 2.254(3)Å	
Fe2 Cl3 2.3322(11)Å	

Table 2: Main metal-ligand distances and angles of the (MeO)₂TPAFeClOFeCl₃.

Reactivity in the presence of substrate.

The oxygenation mechanism of the complexes, shows that at some point an intermediate Fe^(IV) - oxo species is formed. This species is very oxidizing, during the reaction in the absence of substrate, it reacts with a complex molecule to form a μ -oxo diferric species. It would therefore be conceivable that such species, in the presence of cyclohexane as substrate, is capable of transferring oxygen to lead to the formation of an oxidized substrate.

The oxidation of cyclohexane to cyclohexanone has already been studied with ferrous chloride salt and TPA complexes. Therefore, the obtained complexes were reacted with cyclohexane in the presence of O₂. We used zinc amalgam as the Fe^(III) / Fe^(II) reducing agent to regenerate reactive species during the reaction. In a schlenk tube, we prepared a solution of known concentration of complex dissolved in acetonitrile, we then added cyclohexane, a few drops of zinc amalgam, with bubbling oxygen. After one to two hours, a grayish solution is obtained, the acetophenone is added in a known quantity and the whole is filtered through celite. Acetophenone is used as a reference for gas chromatography analysis.

The first signal appears at 4.1 minutes and corresponds to the acetonitrile peak, which is the most intense. Then a few seconds later follows the cyclohexane signal, a low intensity peak. At around 6.6 minutes, the appearance of cyclohexanone is observed, a very weak peak and at the end of 11.6 minutes the reference signal, acetophenone, appears. The relationship below makes it possible to calculate the concentration of cyclohexanone and therefore the turn over number (TON):

$$[\text{cyclohexanone}] = 1.2 [\text{acetophenone}] * \text{Aire}(\text{cyclohexanone}) / \text{Aire}(\text{acetophenone})$$

$$\text{TON} = [\text{cyclohexanone}] / [\text{catalyst}]$$

In the Table below, are listed the results obtained:

	FeCl ₂	TPAFeCl ₂	MeOTPAFeCl ₂	(MeO) ₂ TPAFeCl ₂
TON	=0.4	=8	=29	=40

Table 3: the conversion turnover (TON) of cyclohexane to cyclohexanone and cyclohexane to cyclohexanol.

Mechanistic considerations

The ferric series μ-oxo type complexes constitute a class of derivatives well known in inorganic chemistry. Aside from the chemistry of porphyrins, their mechanism of formation is not fully studied. They are generally obtained by mixing ferric salts FeCl₃ nH₂O, or even Fe(ClO₄)₃ n H₂O with the ligands, most of the time in a protic medium or in the presence of alcohols, without taking special precautions.

How is the μ-oxo bridge created then? Is it by deprotonation of hydroxo ligands (and by what base)?, by oxidation of bound hydroxides [30,45-52]?, or is air oxygen involved? The question has been persistent for many years, without any concluding results.

From ferrous derivatives and molecular oxygen, a simple mechanism was postulated some thirty years ago in porphyrin chemistry [31-50-60]. It is better known as the "autoxidation of ferroporphyrins" mechanism. This mechanism as published is reproduced in Figure 9.

One equivalent of dioxygen reacts with one equivalent of ferrous derivative, to give the adduct product B[59-70]. The later will react with the starting product via the free doublet of coordinated oxygen. The μ -peroxo C species is formed, and undergoes a homolytic cleavage which leads to the formation of the oxo-ferryl species D[70-83]. D reacts again on A to form the final μ -oxo compound E. Four equivalents of complex were necessary to cut one equivalent of the oxygen molecule.




Figure 9 : diagram known as autoxidation of porphyrins. The stable forms are A and E. Only the C form could be detected during this process.

A mechanism similar to that described in porphyrin chemistry can be postulated. It is presented in Figure 10. The stable species detected after oxygenation are indicated on a gray background: μ -oxo derivatives, symmetric, asymmetric, μ -dichloro derivative.

The formation of μ -dichloro species can be explained by the presence of background salt, that could lead to complex dinucleation. The process described in Figure 10 is likely to generate cationic species, and therefore increase the ionic strength of the medium, thus making chloride ions more labile. For technical reasons, we were unable to carry out precise measurements of oxygen uptake by our complexes.




Figure 10 : Adaptation of the autoxidation scheme of porphyrins to the chemistry of simple dichloroferrous complexes in the TPA series.

Conclusion

In the present report a series of methoxy group substituted TPA ligands were synthesized, characterized and complexed with FeCl₂. This type of ligand is Electrothunder. The desire to create such ligands was not trivial, in fact the original purpose was to demonstrate and study the reactivity between Electrothunder and Electrodeficient Ligand which has been fully studied, this will demonstrate the different speed of O₂ coordination at the complex. The prepared complexes were characterized by different spectroscopic techniques, which made it possible to predict their geometry both in solution and in the solid state for (MeO)₂TPAF₂FeCl₂ and MeOTPAFeCl₂ as previously shown . In addition, the reactivity of the complexes in the presence of substrate (cyclohexane) was studied, this reaction was indeed catalytic, in fact multiple cycles are observed, and clean since it leads to the formation of ketone and not alcohol. From the results in Table 2 we should have obtained alcohol since we assumed that the oxidizing species is the intermediate Fe(IV)-oxo. Therefore, mechanistic studies are to be expected.

References:

- 1- Heidi, E.; Bjorgo. E.; Flatmark T.; and Stevens R. C.; *Biochimistry* 2000, 39, 2208-2217.
- 2- Malek, Z.S.; Sage D.; Pevet, P.; Raison, S.; *Endocrinology* 2007, 148 (11), 5165-5173
- 3- Malek, Z.S.; Dardente, H.; Pevet, P.; Raison, S.; *European Journal of Neuroscience* 2005, 22 (4), 895-901.
- 4- Malek, Z.S.; Pevet, P.; Raison, S.; *Neuroscience* 2004, 125 (3), 749-758.
- 5- Malek, Z.S.; Labban, L.; *The International Journal of Neuroscience*, 2020, 1-7.
- 6- Malek, Z.S.; Labban, L.; *European Journal of Pharmaceutical and Medical Research* 2019, 6 (11), 527-532.
- 7- Malek, Z.S.; *Journal of AlBaath University* 2018, 40 (4), 39-62
- 8- Malek, Z.S.; *Tishreen University Journal for Research and Scientific Studies*, 2018, 40
- 9- Kappock, T. J; Caradonna, J. P.; *Chem.Rev.* 1996, 96, 2659-2756.
- 10- Solomon, E. I.; Brunold, T. C.; Mindy I. D.; Kemsley, J. N.; Sang-Kyu Lee.; Lehnert, N.; Neese, F.; Skulan, A. J.; Yi-Shan Y.; and Jing Z.; *Chem.Rev.* 2000, 100, 235-349.
- 11- Goodwill, K. E.; Sabatier, C.; and Stevens, R. C.; *Biochemistry* 1998, 37, 13437-13445.
- 12- Wang Lin.; Erlandsen, H.; Haavik, J.; Knappskog, P. M.; and Stevens R. C , *Biochemistry* 2002, 41, 12569-12574.
- 13- Nordlund P.; in *Handbook of Metalloproteins* (Eds.: I. Bertini,A. Sigel, H. Sigel), Marcel Dekker, New York, 2001, pp. 461 -570.
- 14- Xia, T.; Gray, D. W. ; Shiman, R. J.; *Biol. Chem.* 1994, 269, 24657-24665.
- 15- Francisco W. A.; Tian G.; Fitzpatrick P. F.; and Klinman J. P , *J. Am. Chem. Soc.*;1998, 120, 4057 -4062.
- 16- Arianna B.; Margareta R.A.; Per E.M .S.; *Chem. Eur. J.* 2003, 9,106-115
- 17- Flatmark T.; Stevens R. C.; *Chem. Rev.* 1999, 99, 2137-2160
- 18- Kemsley, J. N. ; Mitic, N.; Loeb-Zaleski, K.; Cradonna, J. P.; Solomon, E. I.; *J. Am. Chem. Soc.* 1999, 121, 1528-1536.
- 19- Dix, T. A.; Kuhn, D. M.; Benkovic, S. J.; *Biochemistry* 1987, 26, 3353-3361.
- 20- Hillas, P. J.; Fitzpatrick, P. F.; *Biochemistry* 1996, 35, 6969-6975.
- 21- Dix, T. A.; Bollag, G. E.; Domanico, P. L.; Benkovic, S. J.; *Biochemistry* 1985, 24, 2955-2958.
- 22- Gardner, H. W.; *Biochim. Biophys. Acta* 1991, 1084, 221-239.
- 23- Mandon, D., Machkour, A., Goetz, S., Welter, R., *Inorg. Chem.*, 2002, 41, 5364 – 5372.
- 24- Thallaj, N., Machkour, A., Mandon, D., Welter, R., *New. J. Chem.*, 2005, 29, 1555 – 1558
- 25- Machkour, A., Mandon, D., Lachkar, M., Welter, R., *Inorg. Chim. Acta*, 2005, 358, 839 – 843.

- 26- Bioinorganic Chemistry : A short course. Roat-Malone, R.M., Wiley Interscience. 2002.
- 27- Solomon, E. I., Brunold, T. C., Davis, M. I., Kemsley, J. N., Lee, S. K., Lehnert, N., Neese, F., Skulan, A. J., Yang, Y. S., Zhou, J., Chem. Rev., 2000, 100, 235-349.
- 28- Coordination Chemistry Reviews 200-202, 2000, 443-485
- 29- Kryatov, S.V., Rybak-Akimova, E.V., MmacMurdo, V.L., Que, L.Jr., Inorg Chem 2001, 40, 2220-2228 and many references herein.
- 30- Michael P .Jensen ,Steven J.Lange, Mark, Emily L.que And Lawrence Que , Jr. JACS ,2003, 125, 2113-2128.
- 31- Lehnert, N., Ho, R.Y.N., Que, L.Jr., Solomon, E.I., J. Am Chem Soc., 2001, 123, 8271-8290.
- 32- Costas, M., Tipton A.K., Chen, K., Jo, D.H., Que, L.Jr, J. Am Chem Soc., 2001, 123, 6722-6723.
- 33- Jo, D.H., Chiou, Y.M., Que, L.Jr., J.Am.Chem.Soc., 2001, 40, 3181-3190.
- 34- Chiou, Y.M., Que, L.Jr., J.Am.Chem.Soc., 1995, 117, 3999-4013.
- 35- Zang, Y., Que, L., Jr., Inorg Chem 1995, 34, 1030-1035.
- 36- Mandon, D., Machkour, A., Goetz, S., Welter, R., Inorg. Chem 2002., Vol.41, No.21,
- 37- Machkour A, Thallaj NK, Benhamou L, Lachkar M, Mandon D. Chemistry. 2006 Aug 25;12(25):6660-8. P 6660-6661-6662-6663.
- 38- Thallaj, N., Machkour, A., Mandon, D., Welter, R., New. J. Chem., 2005, 29, 1555 – 1558.
- 39- Thallaj, N. K. Damascus University Journal for Basic Sciences. 34 (1) 2018.
- 40- Thallaj. N. K. Journal of AlBaath University (39) 2017.
- 41- Thallaj. N. K. Tishreen University Journal for Research and Scientific Studies 38 (6) 2016.
- 42- Thallaj NK, Rotthaus O, Benhamou L, Humbert N, Elhabiri M, Lachkar M, Welter R, Albrecht-Gary AM, Mandon D. Chemistry. 2008;14(22):6742-53. P6745-6746-6747..
- 43- Wane A, Thallaj NK, Mandon D. Chemistry. 2009 Oct 12;15(40):10593-602. P10594-10595-10595.
- 44- Thallaj NK, Orain PY, Thibon A, Sandroni M, Welter R, Mandon D. Inorg Chem. 2014 Aug 4;53(15):7824-36. P7826-7827-7828.
- 45- N. K. Thallaj, J. Przybilla, R. Welter and D. Mandon, J. Am. Chem. Soc. 2008, 130, 2414-2415.
- 46- N. K. Thallaj, D. Mandon and K. A. White, Eur. J. of Inorg. Chem., 2007, 44–47.
- 47- N. K. Thallaj, A. Machkour, D. Mandon and R. Welter, New J. Chem., 2005, 29, 1555–1558.
- 48- Thallaj, N.; International journal of applied chemistry and biological sciences 2021, 2 (4), 65-77.
- 49- Thallaj, N.; Indian Journal of Advanced Chemistry (IJAC)2021, 1 (2), .
- 50- Thallaj, N.; International Journal of Research Publication and Reviews (IJRPR)2021, 2, 10, 951-959
- 51- L. Labban, N. Thallaj, Z. Malek; International Journal of Medical Studies, 2020, 5, No 12, 23-36.
- 52- L. Labban, M. Kudsi, Z. Malek, N. Thallaj; Advances in Medical, Dental and Health Sciences, 2020,3, 3,45-48.
- 53- L. Labban, N. Thallaj, M. Al Masri; Journal of Advanced Research in Food Science and Nutrition, 2020,3,1,34-41.
- 54- Thallaj, N; agha, M. I ,H; , nattouf; A.H; katib, CH; karaali, A; Moustapha, A; Labban L; open access library journal, 2020,7,5,1-21.
- 55- L. labban; N. thallaj; A. labban; archives of medicine, 2020, 12, 2:8, 1-5.
- 56- L. labban; N. thallaj; international journal of herbal medicine, 2020, 8, 2, 33-37.
- 57- L. Labban, N. Thallaj, Z. Malek; Journal of Medical Research and Health Sciences, 2019, 2, 11, 784-787.
- 58- L. labban N. Thallaj; acta scientific nutritional health, 2019, 3,10, 7-12.
- 59- Malek, Z.S.; Sage D.; Pevet, P.; Raison, S.; Endocrinology 2007, 148 (11), 5165-5173.
- 60- Malek, Z.S.; Dardente, H.; Pevet, P.; Raison, S.; European Journal of Neuroscience 2005, 22 (4), 895-901.
- 61- Malek, Z.S.; Pevet, P.; Raison, S.; Neuroscience 2004, 125 (3), 749-758.
- 62- Malek, Z.S.; Labban, L.; The International Journal of Neuroscience, 2020, 1-7.
- 63- Malek, Z.S.; Labban, L.; European Journal of Pharmaceutical and Medical Research 2019, 6 (11), 527-532.
- 64- Malek, Z.S.; Journal of AlBaath University 2018, 40 (4), 39-62.
- 65- Malek, Z.S.; Tishreen University Journal for Research and Scientific Studies, 2018, 40.
- 66- ZS Malek, LM Labban; International Journal of Neuroscience, 2021,131 (12), 1155-1161.

- 67- ZS Malek, LM Labban; Journal of current research in physiology and pharmacology, 2020, 4, (1),1-5.
- 68- L.M. Labban, M. M. Alshishkli, A. Alkhalaf, Z. Malek; J. Adv. Res. Dent. Oral Health, 2017, 2(3&4), 1-4.
- 69- L Labban, ZS Malek, Open Access Library Journal, 2018, 5 (07), 1-11.
- 70- L Labban, ZS Malek, Ann Food Nutr Res J, 2019,1 ,1
- 71- Labban, L. and N. Thallaj, 2019. Acta Scient. Nutr. Health, 3: 7-12.
- 72- A Abbood, C Smadja, C Herrenknecht, Y Alahmad, A Tchaplaj, M Taverna Journal of Chromatography A 1216 (15), 3244-3251
- 73- A Abbood, C Smadja, M Taverna, C Herrenknecht Journal of Chromatography A 1217 (4), 450-458
- 74- A Abbood, C Herrenknecht, G Proczek, S Descroix, J Rodrigo, M Taverna, Analytical and bioanalytical chemistry 400 (2), 459-468
- 75- A Abbood, C Smadja, M Taverna, C Herrenknecht Journal of Chromatography A 1498, 155-162.
- 76- Y. alhomush, Z. malek, A. Abboud, N.Thallaj, Research Journal of Pharmacy and Technology, 2022, 15, 10.
- 77- N.Thallaj, Tishreen university journal,2022,44, 1, 59-77.
- 78- N.Thallaj, Tishreen university journal,2022,44,2.
- 79- Z. Malek, H. Dardente, S. Raison, P. Pevet, Mesocricetus auratus neuronal tryptophan hydroxylase mRNA, partial cds, 2003, GenBank, AY345967.1.
- 80- N.Thallaj. Indian journal of advanced chemistry, 1, 3, 2022. 10-14.
- 81- N.Thallaj. Indian journal of advanced chemistry, 1, 3, 2022. 5-9.
- 82- N.Thallaj Biomedicine and Chemical Sciences 1(2) (2022) 47-56
- 83- N.Thallaj. Journal of Science and Technology. 7,2 ,2022. 54-76